Intuitive Surgical (NASDAQ:ISRG) Given New $425.00 Price Target at Evercore ISI

Intuitive Surgical (NASDAQ:ISRG) had its price objective boosted by Evercore ISI from $385.00 to $425.00 in a research note published on Tuesday, Benzinga reports. They currently have an in-line rating on the medical equipment provider’s stock.

ISRG has been the topic of several other reports. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a buy rating in a research report on Monday, April 8th. BTIG Research upped their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a buy rating in a report on Friday, April 19th. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a hold rating in a report on Friday, April 19th. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an outperform rating on the stock in a report on Friday, April 19th. Finally, Piper Sandler upped their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an overweight rating in a report on Friday, April 19th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, Intuitive Surgical presently has an average rating of Moderate Buy and a consensus price target of $404.79.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $438.81 on Tuesday. The company’s 50-day moving average price is $405.17 and its two-hundred day moving average price is $384.28. Intuitive Surgical has a one year low of $254.85 and a one year high of $448.10. The stock has a market capitalization of $155.65 billion, a PE ratio of 79.21, a price-to-earnings-growth ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the firm posted $1.00 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. On average, analysts anticipate that Intuitive Surgical will post 4.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the transaction, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,037,149.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,037,149.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Myriam Curet sold 5,318 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the sale, the executive vice president now owns 298 shares in the company, valued at approximately $110,456.68. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock worth $6,927,011 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

Institutional Trading of Intuitive Surgical

Several large investors have recently made changes to their positions in ISRG. Marcum Wealth LLC lifted its stake in Intuitive Surgical by 1.7% in the 2nd quarter. Marcum Wealth LLC now owns 2,660 shares of the medical equipment provider’s stock valued at $1,183,000 after purchasing an additional 44 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its stake in Intuitive Surgical by 13.8% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 1,058 shares of the medical equipment provider’s stock valued at $471,000 after purchasing an additional 128 shares during the last quarter. GAMMA Investing LLC lifted its stake in Intuitive Surgical by 38.3% in the 2nd quarter. GAMMA Investing LLC now owns 3,879 shares of the medical equipment provider’s stock valued at $1,726,000 after purchasing an additional 1,075 shares during the last quarter. Transcend Capital Advisors LLC lifted its stake in Intuitive Surgical by 197.6% in the 2nd quarter. Transcend Capital Advisors LLC now owns 3,315 shares of the medical equipment provider’s stock valued at $1,475,000 after purchasing an additional 2,201 shares during the last quarter. Finally, Objective Capital Management LLC lifted its stake in Intuitive Surgical by 11.8% in the 1st quarter. Objective Capital Management LLC now owns 728 shares of the medical equipment provider’s stock valued at $291,000 after purchasing an additional 77 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.